GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Summary

This is a non-randomized, Phase 2, 2-stage, open-label, multi-center study of GRN-1201/sargramostim + pembrolizumab in subjects with PD-L1+ metastatic NSCLC. All subjects will have newly diagnosed metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Subjects with EGFR or ALK genomic tumor aberrations with progression on FDA-approved therapy for these aberrations are eligible

Timeline

Start

2019-01-03

Primary completion

2022-12-05

Completion

2022-12-05

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment rate too slow”

Drugs

Indications